Richard P Sandor, MD
Sports Medicine · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 3 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
3 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sandor’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
3 of 3 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G52651 · Current
Licensed to practise in California · since 1984 · expires 2027-09-30 · University of Arizona College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$108,924
Medicare paid this office $108,924 for 368 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 75 | $35,892 | None |
| Aspiration and/or injection of fluid from large joint | 152 | $27,294 | $68 |
| Short return visit (20+ min) | 175 | $19,843 | $79 |
| New patient visit (30+ min) | 144 | $13,988 | $97 |
| Return visit (30+ min) | 44 | $5,430 | $116 |
See all 6 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 75 | $35,892 | None |
| Aspiration and/or injection of fluid from large joint | 152 | $27,294 | $68 |
| Short return visit (20+ min) | 175 | $19,843 | $79 |
| New patient visit (30+ min) | 144 | $13,988 | $97 |
| Return visit (30+ min) | 44 | $5,430 | $116 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 94 | $318 | None |
Who their Medicare patients are
368 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 64% · Also on Medicaid 15% · Health risk score 1.00. At or below the middle of the specialty; the typical sports medicine clinician is at 1.05.
Conditions among them: High blood pressure 64% · Diabetes 26% · Depression 19% · Chronic kidney disease 18% · Coronary heart disease 17% · Cancer 15% · Atrial fibrillation 13% · COPD 10% · Heart failure 8% · Stroke 7% · Dementia 4%.
The office billed $477,008, Medicare allowed $146,463 and paid $108,924; for 2,292 services of 16 kinds; $39,991 of it was for drugs given in the office and $68,933 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 368 | 2,292 | 77 | 1.00 | $477,008 | $108,924 |
| 2023 | 415 | 3,754 | 77 | 0.89 | $593,023 | $138,125 |
| 2022 | 383 | 2,561 | 76 | 0.87 | $443,830 | $116,545 |
| 2021 | 415 | 1,675 | 76 | 0.91 | $421,947 | $108,282 |
| 2020 | 373 | 1,789 | 76 | 0.92 | $397,273 | $89,688 |
| 2019 | 403 | 1,377 | 76 | 0.92 | $375,676 | $117,987 |
| 2018 | 386 | 1,381 | 76 | 1.03 | $331,541 | $81,116 |
| 2017 | 331 | 1,289 | 75 | 0.96 | $276,788 | $68,262 |
| 2016 | 359 | 1,489 | 76 | 0.99 | $301,890 | $77,165 |
| 2015 | 370 | 1,374 | 75 | 1.18 | $287,550 | $73,594 |
| 2014 | 309 | 1,366 | 75 | 0.92 | $247,029 | $60,110 |
| 2013 | 303 | 1,456 | 74 | 0.91 | $248,226 | $61,848 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 93 | $52,040 | None |
| Aspiration and/or injection of fluid from large joint | 174 | $37,363 | $73 |
| New patient visit (30+ min) | 185 | $18,468 | $100 |
| Short return visit (20+ min) | 166 | $17,810 | $80 |
| Return visit (30+ min) | 62 | $6,792 | $108 |
| Short return visit | 21 | $1,094 | $50 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 101 | $419 | None |
2022: 7 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 70 | $39,057 | None |
| Aspiration and/or injection of fluid from large joint | 149 | $28,041 | $69 |
| New patient visit (30+ min) | 186 | $18,751 | $101 |
| Short return visit (20+ min) | 151 | $16,478 | $83 |
| Return visit (30+ min) | 58 | $6,973 | $118 |
| Short return visit | 12 | $785 | $56 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 100 | $381 | None |
2021: 8 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 51 | $30,059 | None |
| Aspiration and/or injection of fluid from large joint | 134 | $22,815 | $70 |
| New patient visit (30+ min) | 204 | $20,608 | $101 |
| Short return visit (20+ min) | 174 | $18,851 | $82 |
| Return visit (30+ min) | 58 | $7,056 | $120 |
| New patient visit (45+ min) | 15 | $2,433 | $162 |
| Short return visit | 23 | $1,185 | $52 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 92 | $417 | None |
2020: 8 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 46 | $26,361 | None |
| Aspiration and/or injection of fluid from large joint | 115 | $19,203 | $68 |
| New patient visit (30+ min) | 176 | $17,196 | $98 |
| Short return visit (20+ min) | 147 | $12,028 | $66 |
| Return visit (30+ min) | 65 | $5,825 | $90 |
| New patient visit (15+ min) | 20 | $1,421 | $71 |
| Short return visit | 22 | $976 | $44 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 80 | $381 | None |
2019: 8 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 43 | $52,024 | None |
| Aspiration and/or injection of fluid from large joint | 123 | $19,224 | $60 |
| New patient visit (30+ min) | 184 | $17,949 | $98 |
| Short return visit (20+ min) | 193 | $17,153 | $66 |
| Return visit (30+ min) | 56 | $5,539 | $99 |
| New patient visit (15+ min) | 27 | $2,007 | $74 |
| Short return visit | 18 | $759 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 96 | $236 | None |
2018: 8 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 34 | $19,768 | None |
| New patient visit (30+ min) | 182 | $16,862 | $93 |
| Aspiration and/or injection of fluid from large joint | 119 | $16,705 | $53 |
| Short return visit (20+ min) | 171 | $15,956 | $64 |
| Return visit (30+ min) | 64 | $5,754 | $89 |
| New patient visit (15+ min) | 17 | $1,132 | $67 |
| Short return visit | 24 | $1,066 | $41 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 100 | $408 | None |
2017: 8 services
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 32 | $17,842 | None |
| Aspiration and/or injection of fluid from large joint | 95 | $13,946 | $58 |
| Short return visit (20+ min) | 153 | $12,844 | $59 |
| New patient visit (30+ min) | 141 | $12,118 | $86 |
| Return visit (30+ min) | 62 | $5,648 | $91 |
| Short return visit | 30 | $1,179 | $39 |
| New patient visit (15+ min) | 14 | $989 | $71 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 82 | $516 | None |
2016: 11 services
| Aspiration and/or injection of fluid from large joint | 82 | $14,624 | $58 |
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 23 | $14,331 | None |
| Short return visit (20+ min) | 159 | $13,417 | $60 |
| New patient visit (30+ min) | 113 | $10,102 | $89 |
| Return visit (30+ min) | 84 | $7,778 | $89 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 15 | $7,709 | None |
| New patient visit (15+ min) | 66 | $4,101 | $62 |
| Injection into tendon or ligament | 18 | $968 | $51 |
| Short return visit | 23 | $885 | $37 |
| Aspiration and/or injection of fluid from small joint | 13 | $555 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 91 | $468 | None |
2015: 11 services
| Aspiration and/or injection of fluid from large joint | 90 | $14,388 | $55 |
| Short return visit (20+ min) | 152 | $13,449 | $66 |
| New patient visit (30+ min) | 133 | $13,369 | $101 |
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 14 | $9,473 | None |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 15 | $7,282 | None |
| Return visit (30+ min) | 76 | $7,225 | $94 |
| New patient visit (15+ min) | 57 | $3,617 | $63 |
| Injection into tendon or ligament | 19 | $1,047 | $50 |
| Short return visit | 18 | $729 | $38 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 105 | $547 | None |
| Aspiration and/or injection of fluid from small joint | 11 | $464 | $42 |
2014: 9 services
| Short return visit (20+ min) | 158 | $15,473 | $63 |
| Aspiration and/or injection of fluid from large joint | 88 | $12,925 | $49 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 24 | $9,091 | None |
| New patient visit (30+ min) | 101 | $8,563 | $85 |
| Return visit (30+ min) | 80 | $7,910 | $92 |
| New patient visit (15+ min) | 27 | $1,724 | $64 |
| Short return visit | 20 | $872 | $40 |
| Injection into tendon or ligament | 13 | $670 | $52 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 88 | $559 | None |
2013: 9 services
| Aspiration and/or injection of fluid from large joint | 99 | $14,327 | $50 |
| Short return visit (20+ min) | 158 | $14,115 | $63 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 21 | $10,908 | None |
| New patient visit (30+ min) | 80 | $7,379 | $92 |
| Return visit (30+ min) | 78 | $7,255 | $92 |
| New patient visit (15+ min) | 42 | $2,504 | $60 |
| Injection into tendon or ligament | 21 | $1,347 | $50 |
| Short return visit | 23 | $1,091 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 120 | $679 | None |
Medicaid work
$296 in 2023
Medicaid paid $296 for 29 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Arthrocentesis and injection of knee joint | 29 | $296 |
| 2023 | 29 | 1 | 12 | $296 |
Money from drug and device companies
$15 in 2019
A payment is not proof that care is biased.
| DePuy Synthes Sales | Orthovisc | $15 | 1 payment
|
See the published payment
| DePuy Synthes Sales | Meals · 2019-03-07 | Orthovisc | $15 |
Professional record
- NPI
- 1649351131
- Licence
- CA G52651California G52651: Current · expires 2027-09-30
- Trained
- University of Arizona College of Medicine, 1983
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RS0010X (207RS0010X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-10-18
- NPI last updated
- 2021-02-04
- NPI record certified
- 2021-02-04
This is when the NPI record was last certified, not a medical board exam.